Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: Results of an open-label observational study

Pillunat L.E., Erb C., Ropo A., Kimmich F., Pfeiffer N.

2017
Clinical Ophthalmology

View publication

Therapeutic Area

Glaucoma
Categories

Post-Approval studies/RWE

Affiliations

Department of Ophthalmology, University Hospital Carl Gustav Carus, Dresden, Germany; Augenklinik am Wittenbergplatz, Berlin, Germany; Santen Europe, Helsinki, Finland; Eyecons, Pfinztal, Germany; Department of Ophthalmology, Mainz University Medical Center, Mainz, Germany

Related Publications

Long-term safety and efficacy of sepetaprost, with or without timolol, in patients with open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J2 study

Inatani M., Tone Y., Ikeda T., Angeles R.

Efficacy and safety of sepetaprost in patients with primary open-angle glaucoma or ocular hypertension: results from the randomised, phase 3 ANGEL-J1 study

Inatani M., Kanamori A., Inai M., Ikeda T., Angeles R.

Clinical outcomes of Preserflo MicroShunt implant procedure in open‑angle glaucoma patients – a 1000 eyes case-series; including subanalysis of combined cataract-glaucoma surgery and standalone surgery in pseudophakic eyes

Klabe, K.; Werth, J.P.; Kaymak, H. ; Fricke, A.

View all Glaucoma publications

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022